QSAM Biosciences Appoints Richard K. Burt, M.D., Pioneer in the Use of Stem Cell Transplants to Treat Autoimmune Diseases, to Scientific Board of Advisors
28 avr. 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, April 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...
QSAM Biosciences Issues Letter from CEO on Successful Achievements and Future Milestones for Company
19 avr. 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, April 19, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today: Dear...
QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
17 mars 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the...
QSAM Biosciences Appoints Charles J. Link, Jr., M.D., Experienced Biotech Executive and Innovator, to Board of Directors
16 févr. 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, Feb. 16, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...
QSAM Biosciences Clarifies Recent Promotional and Trading Activities at the Request of OTC Markets
11 févr. 2021 18h08 HE
|
QSAM Biosciences Inc.
Austin, Texas;, Feb. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM” or the “Company”), today announced that it became aware on February 9, 2021 of certain promotional...
QSAM Biosciences Closes Series B Preferred Private Placement; $2.5 Million in New Capital to Fund Upcoming Clinical Trials
28 janv. 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, Texas, Jan. 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases,...
QSAM Biosciences Receives Favorable Safety Results in Study for its Leading Radiopharmaceutical Drug Candidate
21 janv. 2021 09h00 HE
|
QSAM Biosciences Inc.
Palm Beach, FL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines for the treatment of cancer and related diseases and...
QSAM Biosciences Receives Notice of Allowance for European Patent and Expands Licensed IP Portfolio
10 déc. 2020 09h00 HE
|
QSAM Biosciences Inc.
Palm Beach, FL, Dec. 10, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Cyclosam® Samarium-153-DOTMP, for the...
QSAM Biosciences Issues Letter from New CEO; Presents Opportunities Ahead for Company
24 nov. 2020 09h00 HE
|
QSAM Biosciences Inc.
Palm Beach, FL, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The recently appointed Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided in the following letter to...
QSAM Biosciences Advances Plan of Separation from Legacy Business
10 nov. 2020 09h00 HE
|
QSAM Biosciences Inc.
Pharmaceutical Industry Experts Assume Leadership Roles at QSAM;Over $4M in Debt Eliminated from Balance Sheet Palm Beach, FL, Nov. 10, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM)...